Smither John W
SEC Form 4 insider trading activity
Smither John W has filed 6 SEC Form 4 filings (18 transaction rows) across 3 companies, including NAMS, MBX, GNLX, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Sep 9, 2026.
On the most recent filing, Smither John W is listed as Director at NewAmsterdam Pharma Co N.V. Inside the rolling window, Smither John W reported no open-market purchases and 2 open-market sales totaling $75K in NAMS and GNLX. The largest disclosed transaction in the window is a sale of 1,600 NAMS shares on Sep 4, 2026, worth $41K.
Companies traded
Other insiders at NAMS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$75K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Smither John W made?
Smither John W has filed 6 SEC Form 4 filings (18 transaction rows) across 3 companies, including NAMS, MBX, GNLX since 2025.
Which companies does Smither John W trade?
Smither John W has filed SEC Form 4 disclosures for 3 companies, including NAMS, MBX, GNLX.
When was Smither John W's most recent SEC Form 4 filing?
Smither John W's most recent SEC Form 4 filing on Tracefour is dated Sep 9, 2026.
What is Smither John W's total buy and sell value in the current window?
Inside the rolling retention window, Smither John W bought $0 and sold $75K based on SEC Form 4 filings.
What was Smither John W's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,600 NAMS shares on 2026-09-04, worth $41K, per SEC Form 4 filings.